Te. Allen et B. Ullman, CLONING AND EXPRESSION OF THE HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE GENE FROM TRYPANOSOMA-BRUCEI, Nucleic acids research, 21(23), 1993, pp. 5431-5438
The hypoxanthine-guanine phosphoribosyltransferase (HGPRT) enzyme of T
rypanosoma brucei and related parasites provides a rational target tor
the treatment of African sleeping sickness and several other parasiti
c diseases. To characterize the T. brucei HGPRT enzyme in detail, the
T. brucei hgprt was isolated within a 4.2 kb San-KpnI genomic insert a
nd sequenced. Nucleotide sequence analysis revealed an open reading fr
ame of 630 bp that encoded a protein of 210 amino acids with a M(r) =
23.4 kd. After gap alignment, the T. brucei HGPRT exhibited 21 - 23% a
mino acid sequence identity, mostly in three clustered regions, with t
he HGPRTs from human, S. mansoni, and P. falciparum, indicating that t
he trypanosome enzyme was the most divergent of the group. Surprisingl
y, the T. brucei HGPRT was more homologous to the hypoxanthine phospho
ribosyltransferase (HPRT) from the prokaryote V. harveyi than to the e
ukaryotic HGPRTs. Northern blot analysis revealed two trypanosome tran
scripts of 1.4 and 1.9 kb, each expressed to equivalent degrees in ins
ect vector and mammalian forms of the parasite. The T. brucei hgprt wa
s inserted into an expression plasmid and transformed into Sphi606 E.
coli that are deficient in both HPRT and xanthine-guanine phosphoribos
yltransferase activities. Soluble, enzymatically active recombinant T.
brucei HGPRT was expressed to high levels and purified to homogeneity
by GTP-agarose affinity chromatography. The purified recombinant enzy
me recognized hypoxanthine, guanine, and allopurinol, but not xanthine
or adenine, as substrates and was inhibited by a variety of nucleotid
e effectors. The availability of a molecular clone encoding the T. bru
cei hgprt and large quantities of homogeneous recombinant HGPRT enzyme
provides an experimentally manipulable molecular and biochemical syst
em for the rational design of novel therapeutic agents for the treatme
nt of African sleeping sickness and other diseases of parasitic origin
.